Resolvin D5 n-3 DPA
(Synonyms: 7(S),17(S)-DiHDPE；7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-Docosapentaenoic Acid；7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-DPE；7(S),17(S)-dihydroxy-trans-8,15-cis-10,13,19-Docosapentaenoic Acid；7(S),17(S)-Dihydroxydocosapentaenoic Acid；7() 目录号 : GC27589
一键复制产品信息
Resolvin D5 n-3 DPA is a specialized pro-resolving mediator (SPM).
Cas No.:1609382-32-2
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Resolvin D5 n-3 DPA is a specialized pro-resolving mediator (SPM).[1] It is formed via double oxygenation of docosapentaenoic acid (n-3 DPA; Item Nos. 90165 | 21907) in human leukocytes.[2] Resolvin D5 n-3 DPA induces activation of G protein-coupled receptor 101 (GPR101), GPR32, and GPR18 in β-arrestin recruitment assays using CHO cells expressing the human receptors (EC50s = 4.6, 14, and 1.5 pM, respectively). It increases efferocytosis of apoptotic HL-60 leukemia cells and phagocytosis of S. aureus bioparticles by isolated human monocyte-derived macrophages when used at a concentration of 1 nM. In vivo, Resolvin D5 n-3 DPA (150 ng/animal) prevents weight loss and decreases disease severity and hind paw edema in a K/BxN serum transfer-induced mouse model of inflammatory arthritis. It decreases blood leukocyte activation and aortic lesions in ApoE-/- mice fed a western diet when administered at a dose of 100 ng/animal.[3]Plasma levels of resolvin D5 n-3 DPA are increased in patients with pancreatic ductal adenocarcinoma (PDAC).[4]
References:
1. Flak, M.B., Koenis, D.S., Sobrino, A., et al. GPR101 mediates the pro-resolving actions of RvD5n-3 DPA in arthritis and infections. J. Clin. Invest. 130(1), 359-373 (2020).
2. Dalli, J., Colas, R.A., and Serhan, C.N. Novel n-3 immunoresolvents: Structures and actions. Sci. Rep. 3, 1940 (2013).
3. Colas, R.A., Souza, P.R., Walker, M.E., et al. Impaired production and diurnal regulation of vascular RvDn-3 DPA increase systemic inflammation and cardiovascular disease. Circ. Res. 122(6), 855-863 (2018).
4. Aguirre, G.A., Goulart, M.R., Bank, B.P.T., et al. Arachidonate 15-lipoxygenase-mediated production of Resolvin D5n-3 DPA abrogates pancreatic stellate cell-induced cancer cell invasion. Front. Immunol. 14, 1248547 (2023).
| Cas No. | 1609382-32-2 | SDF | |
| 别名 | 7(S),17(S)-DiHDPE；7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-Docosapentaenoic Acid；7(S),17(S)-dihydroxy-8(E),10(Z),13(Z),15(E),19(Z)-DPE；7(S),17(S)-dihydroxy-trans-8,15-cis-10,13,19-Docosapentaenoic Acid；7(S),17(S)-Dihydroxydocosapentaenoic Acid；7( | ||
| 分子式 | C22H34O4 | 分子量 | 362.5 |
| 溶解度 | DMF: 100 mg/ml ；DMSO: 100 mg/ml；Ethanol: Miscible | 储存条件 | Store at -20°C |
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.7586 mL | 13.7931 mL | 27.5862 mL |
| 5 mM | 551.7 μL | 2.7586 mL | 5.5172 mL |
| 10 mM | 275.9 μL | 1.3793 mL | 2.7586 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: ≥98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet